Treatments for Attention Deficit Hyperactivity Disorder (ADHD) and Related Problems Through Personalized Medicine and Improved Diagnosis

Technology Overview

Attention Deficit Hyperactivity Disorder (ADHD) is a very common problem, affecting 6 to 10% of children. Children with ADHD often have concomitant psychiatric, medical and learning problems, and if untreated, teens with ADHD have a higher chance of school failure and dropout, substance or alcohol abuse and delinquency. Interventions, both through medication use and behavior conditioning therapy, have high proven efficacy in treating ADHD and associated mood disorders in children.

Dr. Mark Stein

Dr. Stein and his group have overseen many clinical trials where their multi-disciplinary diagnostic approaches have been used as the gold standard against which the FDA establishes efficacy for novel ADHD assessment methods. This has placed Dr. Stein and his team in an excellent position to help manage upcoming clinical trials at every stage of development (phase I-IV).

Ongoing work conducted by Dr. Stein’s group has focused significantly on personalized treatment regimens for ADHD and other neurobehavioral disorders, including autism. Two of the initiatives overseen by Dr. Stein that have shown great efficacy are the Program to Evaluate/Enhance Attention, Regulation & Learning (PEARL) clinic, and a summer treatment program called Camp Sea STAR. Both of these initiatives emphasize high levels of direct and personalized therapy to help build social and organizational skills, and have shown significant behavioral improvements in patients over relatively short timeframes. Dr. Stein also conducts research focused on precision medication prescription. This includes the identification of EEG and genetic biomarkers that can guide the selection of the most effective treatment options for individual patients.

Dr. Stein is interested in industry partnerships that leverage his vast experience in ADHD evaluation, including development of mobile apps designed for use in assessing outcomes for clinical trials and for improving treatment adherence; commercial development of treatment programs for ADHD (e.g., summer treatment programs, tutor-based treatment programs), training opportunities for industry partners, and research to identify biomarkers (genetic and EEG) that will facilitate personalized treatment of ADHD, as well as clinical trial management and consultation.

Dr. Stein is interested in industry partnerships that leverage his vast experience in ADHD evaluation, including development of mobile apps designed for use in assessing outcomes for clinical trials and for improving treatment adherence. Furthermore, Dr. Stein is interested in developing commercial treatment programs for ADHD (e.g., summer treatment programs, tutor-based treatment programs), training opportunities for industry partners, and research to identify biomarkers (genetic and EEG) that will facilitate personalized treatment of ADHD, as well as clinical trial management and consultation.

Stage of Development

  • Clinical: Phase I-IV

Partnering Opportunities

  • Collaborative research opportunity
  • Sponsored research agreement
  • Consultation agreement
  • Software/app development

Publications

  1. Snyder S, Rugino T, Hornig M, Stein M. Integration of an EEG biomarker with a clinician’s ADHD evaluation. Brain Behav. 2015;5(4).
  2. Stein M, Waldman I, Newcorn J, Bishop J, Kittles R, Cook E. Dopamine Transporter Genotype and Stimulant Dose-Response in Youth with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology. 2014;24(5):238-244.
  3. Stein M, McGough J. The Pharmacogenomic Era: Promise for Personalizing Attention Deficit Hyperactivity Disorder Therapy. Child and Adolescent Psychiatric Clinics of North America. 2008;17(2):475-490.

Learn More

To learn more about partnering with Seattle Children’s Research Institute on this or other projects, please contact:

Dr. Elizabeth Aylward
Director, Office of Science-Industry Partnerships
Email
206-844-1065